Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
Pancreatic Cancer
DRUG: Oncolytic virus Plus Anti-PD1 and Chemotherapy
Incidence of Treatment-Related Adverse Events [Safety and Tolerability], Defined by treatment-related adverse events as assessed by CTCAE v4.0, through study completion, an average of 1 year
R0 resection rate, defined as complete resection without any macroscopic or microscopic evidence of lesion at the lateral and deep tissue margins, 6 months|ORR, The incidence of CR (complete remission) and PR (partial remission), 6 months
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Oncolytic virus Plus Anti-PD1 and Chemotherapy as Preoperative therapy for Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer